Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study.
Muriel ElhaiMarouane BoubayaOliver DistlerVanessa SmithMarco Matucci-CerinicJuan José Alegre SanchoMarie-Elise TruchetetYolanda Braun-MoscoviciFlorenzo IannonePavel I NovikovAlain LescoatElise SiegertIvan CastellviPaolo AiróSerena VettoriEllen De LangheEric HachullaAnne ErlerLidia AnanievaMartin KruscheF J López-LongoJörg H W DistlerNicolas HunzelmannAnna-Maria Hoffmann-VoldValeria RiccieriVivien M HsuMaria R PozziCodrina AncutaEdoardo RosatoCarina MihaiMasataka KuwanaLesley Ann SaketkooCarlo ChizzoliniRoger HesselstrandSusanne UllmanSule YavuzSimona RednicCristian CaimmiCoralie Bloch-QueyratYannick Allanorenull nullPublished in: Annals of the rheumatic diseases (2019)
Rituximab use was associated with a good safety profile in this large SSc-cohort. Significant change was observed on skin fibrosis, but not on lung. However, the limitation is the observational design. The potential stabilisation of lung fibrosis by rituximab has to be addressed by a randomised trial.
Keyphrases